Pulmatrix (2PU) AI Stock Analysis

0 Followers

Pulmatrix

(Frankfurt:2PU)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

No reported debtThe absence of reported debt reduces interest expense and refinancing pressure, giving Pulmatrix greater flexibility than a similarly loss-making company with leverage. This supports preservation of scarce cash and may help management direct funding toward clinical development and strategic execution.

Negative Factors

No current revenue baseWith effectively no current revenue, Pulmatrix lacks internally generated commercial support for research, operations, or future investment. Its ability to create durable value therefore remains dependent on successful development, partnering, or commercialization of candidates rather than an established sales base.

Pulmatrix (2PU) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.86M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.4
Beta (1Y): 0.90
Revenue Growth: -100.00%
EPS Growth: 52.69%
Country: Germany
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pulmatrix Business Overview & Revenue Model

Company Description

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. C...

Pulmatrix Risk Analysis

Pulmatrix disclosed 72 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Global economic and political instability and conflicts, such as the conflicts in Venezuela, between Russia and Ukraine or in the Middle East, could adversely affect our business, financial condition or results of operations.Q2, 2026

Pulmatrix Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2PU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMRN	52Neutral	$9.06M	-3.10	-31.88%	―	10.41%	42.44%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	51Neutral	$12.04M	-0.77	-64.75%	―	-62.70%	-121.27%
IBIO	42Neutral	$50.11M	-2.46	-47.92%	―	-75.00%	74.04%
FBLG	40Underperform	$6.59M	-0.16	-536.78%	―	―	22.10%
CMMB	38Underperform	$8.55M	-1.20	-70.81%	―	―	56.99%

* Healthcare Sector Average

Performance Comparison

DE:2PU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2PU	Pulmatrix	0.92	-3.12	-77.23%
IBIO	Ibio Inc	0.80	-0.59	-42.45%
LPCN	Lipocine Inc	1.44	-1.20	-45.45%
IMRN	Immuron	0.85	-0.81	-48.67%
CMMB	Chemomab Therapeutics Ltd.	1.23	-1.35	-52.33%
FBLG	FibroBiologics, Inc.	0.97	-5.74	-85.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pulmatrix AI Stock Analysis